Panel Discussion: De-Risking Molecular Glue Development: What Does It Take to Build a Clinically and Commercially Successful Programme?
4:00 pm - Wednesday 27th January 2027
- How can developers integrate proteomics, mechanistic biology, translational biomarkers, and emerging clinical data to identify safety liabilities early and improve confidence in candidate selection?
- What are the most important scientific, clinical, regulatory, and commercial risks facing molecular glue programmes today, and how should biotech leaders, investors, and drug developers assess them when making development and funding decisions?
- As more molecular glues advance toward the clinic, what frameworks are needed to evaluate off-target effects, long-term biological consequences, and programme differentiation to enable informed go/no-go, partnering, and investment decisions?
